ULVR

4,173

0%↓

DGE

1,395

-0.04%↓

ADM

3,204

+1.84%↑

ULVR

4,173

0%↓

DGE

1,395

-0.04%↓

ADM

3,204

+1.84%↑

ULVR

4,173

0%↓

DGE

1,395

-0.04%↓

ADM

3,204

+1.84%↑

ULVR

4,173

0%↓

DGE

1,395

-0.04%↓

ADM

3,204

+1.84%↑

ULVR

4,173

0%↓

DGE

1,395

-0.04%↓

ADM

3,204

+1.84%↑

Strona główna・Stock List・Tate & Lyle PLC

Tate & Lyle PLC

Closed

SectorConsumer defensive

352 -0.9

Buy Sell

Overview

Share price change

24h

Current

Min

351

Max

353.2

Key metrics
By Trading Economics
Income	56M
Sales	1B
P/E Sector Avg	51.714 28.921
Dividend yield	5.57
Profit margin	5.469
Employees	5,000
EBITDA	188M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+17.83% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	5.57% 3.78%
Next Earnings	21 maj 2026

Market Stats
By TradingEconomics
Market Cap	1.6B
Previous open	352.9
Previous close	352

News Sentiment

By Acuity

50%

62 / 131 Ranking in Consumer defensive

Tate & Lyle PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 kwi 2026, 23:17 UTC

Earnings

Samsung Forecasts Record First-Quarter Operating Profit

6 kwi 2026, 23:00 UTC

Hot Stocks

Stocks to Watch: Health Insurers, Mawson, Owlet

6 kwi 2026, 22:13 UTC

Major Market Movers

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6 kwi 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6 kwi 2026, 17:09 UTC

Major Market Movers

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6 kwi 2026, 16:56 UTC

Major News Events

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6 kwi 2026, 14:47 UTC

Major Market Movers

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7 kwi 2026, 00:00 UTC

Major News Events

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6 kwi 2026, 23:58 UTC

Market Talk

Major News Events

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6 kwi 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6 kwi 2026, 23:36 UTC

Market Talk

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6 kwi 2026, 23:15 UTC

Market Talk

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6 kwi 2026, 22:52 UTC

Market Talk

Global Equities Roundup: Market Talk

6 kwi 2026, 22:52 UTC

Market Talk

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6 kwi 2026, 22:14 UTC

Market Talk

Correction to Live Cattle Futures Article

6 kwi 2026, 20:56 UTC

Market Talk

Mexican Private Consumption Fell in January -- Market Talk

6 kwi 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

6 kwi 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 kwi 2026, 19:58 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 kwi 2026, 19:58 UTC

Market Talk

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6 kwi 2026, 19:11 UTC

Market Talk

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6 kwi 2026, 19:06 UTC

Market Talk

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6 kwi 2026, 19:03 UTC

Market Talk

Global Energy Roundup: Market Talk

6 kwi 2026, 19:03 UTC

Market Talk

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6 kwi 2026, 18:36 UTC

Acquisitions, Mergers, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 kwi 2026, 17:59 UTC

Market Talk

Major News Events

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6 kwi 2026, 17:13 UTC

Acquisitions, Mergers, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 kwi 2026, 16:33 UTC

Market Talk

Oil Futures Steady as Market Awaits Trump -- Market Talk

6 kwi 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 kwi 2026, 14:59 UTC

Earnings

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Peer Comparison

Price change

Tate & Lyle PLC Forecast

Price Target

By TipRanks

17.83% upside

12 Months Forecast

Average 415 GBX 17.83%

High 500 GBX

Low 375 GBX

Based on 4 Wall Street analysts offering 12 month price targets forTate & Lyle PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Tate & Lyle PLC - Dist in the past 3 months.

Sentiment

By Acuity

62 / 131 Ranking in Consumer defensive

Financials

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Tate & Lyle PLC

Tate & Lyle plc, together with its subsidiaries, engages in the provision of ingredients and solutions to the food, beverage, and other industries in North America, Asia, Middle East, Africa, Latin America, and Europe. The company operates through three segments: Food & Beverage Solutions, Sucralose, Primary Products Europe, and Primient. It offers dairy products, soups, sauces, and dressings; bakery products and snacks; texturants; sweeteners, such as high fructose corn syrup and dextrose; industrial starches; acidulants; and corn gluten feed and meal and corn oil. The company was incorporated in 1903 and is headquartered in London, the United Kingdom.